GlassScriptPhysician profile
Courtney E Calandro
NPI 1710069455
$6,961.30
in general payments reported to CMS, 2019-2025
26 companies · $2,836 in 2025
The $2,836 reported for 2025 was more than what 95% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $226 · 2022: $430 · 2023: $1,396 · 2024: $2,073 · 2025: $2,836.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,221 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,221.36 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,212.62 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $678.40 | 2022-2025 | Entyvio, Eohilia, Gattex |
| Ardelyx, INC. | $618.52 | 2023-2025 | Ibsrela |
| Qol Medical, LLC | $486.78 | 2023-2025 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $460.16 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Biotech, INC. | $315.98 | 2023-2025 | Tremfya, Stelara, Simponi Aria |
| Ironwood Pharmaceuticals, INC | $271.57 | 2023-2024 | Linzess |
| Celgene Corporation | $239.44 | 2021-2024 | Zeposia |
| Pfizer INC. | $212.97 | 2024-2025 | |
| Ferring Pharmaceuticals INC. | $147.85 | 2023-2025 | Rebyota |
| Lilly USA, LLC | $147.54 | 2024-2025 | Omvoh |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $137.23 | 2023-2025 | Xifaxan, Trulance |
| Aimmune Therapeutics, INC. | $120.53 | 2024-2025 | Vowst, Zenpep |
| Pentax of America, INC. | $115.07 | 2021 | |
| Braintree Laboratories, INC. | $111.56 | 2022-2024 | Sutab, Suflave |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $110.36 | 2023-2025 | |
| Genzyme Corporation | $104.80 | 2023-2025 | |
| Intercept Pharmaceuticals, INC. | $78.07 | 2023-2025 | Ocaliva |
| Vivus LLC | $75.68 | 2025 | Pancreaze |
| Alnylam Pharmaceuticals INC. | $62.87 | 2024-2025 | Givlaari |
| Phathom Pharmaceuticals, INC. | $62.32 | 2024-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $58.20 | 2023-2024 | Dupixent |
| Fresenius Kabi USA, LLC | $50.17 | 2023-2024 | Idacio |
| Mirum Pharmaceuticals, INC. | $41.47 | 2025 | Cholbam, Livmarli, Chenodal |
| Novo Nordisk INC | $25.04 | 2025 | Wegovy |
| Merck Sharp & Dohme LLC | $16.10 | 2024 | Dificid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Courtney Calandro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.